Healthcare Trade Mission to Russia, June 3-7, 2013, 77032-77035 [2012-31425]
Download as PDF
77032
Federal Register / Vol. 77, No. 250 / Monday, December 31, 2012 / Notices
On July 30, 2012, all remaining parties
that had requested an administrative
review during the instant POR withdrew
their requests for review given
petitioners’ filing of a request for a ‘‘no
interest’’ changed circumstances review,
seeking revocation of the Order.
Period of Review
The POR is December 1, 2010,
through November 30, 2011.
Scope of the Order
The merchandise covered by the order
is honey from Argentina. The products
covered are natural honey, artificial
honey containing more than 50 percent
natural honey by weight, preparations of
natural honey containing more than 50
percent natural honey by weight, and
flavored honey. The subject
merchandise includes all grades and
colors of honey whether in liquid,
creamed, comb, cut comb, or chunk
form, and whether packaged for retail or
in bulk form. The merchandise is
currently classifiable under subheadings
0409.00.00, 1702.90.90, and 2106.90.99
of the Harmonized Tariff Schedule of
the United States (HTSUS). Although
the HTSUS subheadings are provided
for convenience and customs purposes,
the Department’s written description of
the merchandise under the order is
dispositive.
mstockstill on DSK4VPTVN1PROD with
Rescission of Antidumping Duty
Administrative Review
As the Order on honey from
Argentina is being revoked, effective as
of the first day of this administrative
review period (i.e., December 1, 2010),14
the Department is rescinding this
administrative review consistent with
19 CFR 351.213(d)(4) and 351.222(g)(4).
Assessment Instructions
Given the revocation of the Order, the
Department will instruct CBP to
terminate suspension of liquidation
effective December 1, 2010. The
Department will instruct CBP to
liquidate without regard to antidumping
duties, all unliquidated entries of the
subject merchandise entered, or
withdrawn from warehouse, for
consumption on or after December 1,
2010. In accordance with section 778 of
the Act, we will also instruct CBP to pay
interest on and refund any AD deposits
with respect to the subject merchandise
entered, or withdrawn from warehouse,
for consumption on or after December 1,
2010, the first day of this administrative
review period, which is now terminated
by virtue of the effective date of the
14 See notice of final results of changed
circumstances review of honey from Argentina
signed concurrently with this notice.
VerDate Mar<15>2010
21:28 Dec 28, 2012
Jkt 229001
revocation. The Department intends to
issue appropriate assessment
instructions to CBP 15 days after the
date of publication of this notice of
rescission of administrative review.
Notification Regarding Administrative
Protective Orders
This notice serves as a reminder to
parties subject to administrative
protective order (APO) of their
responsibility concerning the
disposition of proprietary information
disclosed under APO in accordance
with 19 CFR 351.305(a)(3). Timely
written notification of the return or
destruction of APO materials or
conversion to judicial protective order is
hereby requested. Failure to comply
with the regulations and terms of an
APO is a sanctionable violation.
We are issuing and publishing this
notice in accordance with sections
751(a)(1) and 777(i)(1) of the Tariff Act
of 1930, as amended, and 19 CFR
351.213(d)(4).
Dated: December 20, 2012.
Christian Marsh,
Deputy Assistant Secretary for Antidumping
and Countervailing Duty Operations.
[FR Doc. 2012–31450 Filed 12–28–12; 8:45 am]
BILLING CODE 3510–DS–P
DEPARTMENT OF COMMERCE
International Trade Administration
Healthcare Trade Mission to Russia,
June 3–7, 2013
International Trade
Administration, Department of
Commerce.
ACTION: Notice.
AGENCY:
Mission Description
The U.S. Department of Commerce,
International Trade Administration,
U.S. and Foreign Commercial Service
(CS), is organizing a Healthcare Trade
Mission to Moscow and St. Petersburg,
Russia from June 3–7, 2013 which will
be led by a senior Commerce official.
Russia, with 140 million consumers
and rapidly growing demand for
healthcare products and services,
presents lucrative opportunities for U.S.
companies. Equipment, technologies,
and investments are needed in the
healthcare sector, specifically in the
medical equipment, dental equipment
and biotechnology sub-sectors. This
healthcare mission will directly
contribute to the National Export
Initiative (NEI) by assisting U.S.
businesses in entering the Russian
healthcare market and increasing U.S.
exports. It will also be a deliverable for
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
the U.S.-Russia Bilateral Presidential
Commission Business Development and
Economic Relations Working Group.
The mission will help participants
gain market insights, make industry
contacts, solidify business strategies,
and advance specific projects with the
goal of increasing U.S. exports to Russia.
The mission will include one-on-one
business appointments with prescreened potential partners, market
briefings, and networking events.
Joining this official U.S. delegation will
provide participating companies an
opportunity to assess the Russian
healthcare market.
Commercial Setting
Russia is one of the world’s fastest
growing economies and its healthcare
system is evolving rapidly with a
promising outlook for U.S. healthcare
exports, particularly in the medical
equipment, dental equipment and
biotechnology subsectors. Russia’s
National Health Project aims at
improving access and funding for
healthcare and improving Russia’s
healthcare sector, and has created
opportunities for increased U.S. exports
in the healthcare sector.
Approximately 20% of overall health
care spending is covered out-of- pocket
by patients. Voluntary healthcare
insurance programs currently account
for approximately one-third of total
private healthcare expenditures.
According to future reform plans,
mandatory insurance funds will serve as
the main source of healthcare funding
and will provide transparency and
monetary control within the system.
The National Health Project was
signed by President Putin in 2005 and
was designed to significantly improve
Russian healthcare. From 2011–2013,
$15.4 billion was allocated from both
the federal budget and the Mandatory
Healthcare Insurance Fund [to the
National Health Project?]. The Program
of Modernization in Healthcare 2011–
2012, aimed at renovating and
upgrading healthcare facilities, was
financed at $11 billion. The significant
funding reflects the current need for
new modern technologies for
diagnostics and treatment. Russian
patients are becoming more aware of
modern medical technologies around
the world and expect the same types of
treatment in Russia.
In addition to these programs that are
currently being implemented, the
Ministry of Health has recently
developed a draft government program
called ‘‘Development of Healthcare in
the Russian Federation.’’ This document
is currently under review for approval.
It contains the principles of preventive
E:\FR\FM\31DEN1.SGM
31DEN1
Federal Register / Vol. 77, No. 250 / Monday, December 31, 2012 / Notices
medicine, quality of provided
healthcare services, education of
medical personnel, and overall changes
in the healthcare infrastructure.
The Ministry of Industry and Trade is
also currently developing a strategy for
the development of the medical
industry through 2020. With continued
growth in this sector, World Trade
Organization (WTO) accession, and
government plans to modernize and
invest in Russian healthcare through
2020, American companies should be
poised to make significant contributions
to the Russian healthcare market.
mstockstill on DSK4VPTVN1PROD with
Medical Equipment
The medical equipment sector is one
of the fastest-growing sectors of the
economy. There is a relatively stable
macroeconomic situation in Russia with
much unsatisfied deferred demand for
medical equipment across the country.
In addition, the Russian government is
focused on this sector and has increased
government financing for the purchase
of medical equipment. For example, the
Program of High-Tech Medical
Assistance 2011–2013 was financed at
$4 billion.
In 2011, the market for medical
equipment was estimated at $4.9 billion.
During the next nine years, experts
expect yearly market growth to be
13.5%. The most promising market
segments include diagnostics and
visualization, cardiovascular,
ophthalmology, orthopedics, laboratory
diagnostics and urology equipment and
technology. For example, the average
annual increase from 2006–2011 in
market share for diagnostics and
visualization equipment was 18% and
in medical IT 10%.
Since commercialization of medical
equipment manufactured in Russia
remains low, the market for medical
equipment is heavily dependent on
imports. The average annual increase in
the import market for medical
equipment from 2006 to 2011 was
approximately 23%. Medical equipment
imports in 2006 were $14.2 billion, with
steady growth to $41 billion in 2011.
Membership in the WTO will also
benefit foreign exports to Russia. After
full implementation of the WTO
accession and Permanent Normal Trade
Relations, tariffs for medical equipment
are estimated to range from 0% to 7%.
Currently, tariffs range as high as 15%
to 20%.
Dental Equipment
The Russian dental market is also a
sector that is expanding and showing
good growth potential. In 2011, total
world imports into Russia for dental
equipment were approximately $500
VerDate Mar<15>2010
21:28 Dec 28, 2012
Jkt 229001
million, reflecting the need for dental
equipment for use in the large market
for dental services in Russia, which was
approximately $6 billion in 2011.
The number of clinics, practicing
dentists, technicians and patient visits
are all on the rise. There are over 9,500
dental units operating in Moscow, with
3,000 state clinics and over 6,500
private clinics. There are 670 municipal
dental clinics and 2900 dental
departments within those clinics. The
highest level of dental industry
privatization is in the Moscow region.
The number of practicing dentists in
Russia is 68,000, of which 35,000 are
members of the Russian Dental
Association. The number of patient
visits is approximately 150 million a
year. However, the ratio of dentists to
patients in Russia is still only 45/
100,000 people, which is below levels
in the United States and most European
countries. In the United States, the ratio
of patients to dentists is 60/100,000.
The dental market is one of the most
organized markets in Russia. The largest
associations are the Russian Dental
Association, which has 69 regional
divisions and the Dental Industry (DI
ROSI) which has 45 member companies.
These associations play an important
role in the introduction of new
technologies and practices, actively
participate in trade events, and regularly
publish in professional journals. As a
result, they have a large impact on the
industry. The two major dental
universities are Moscow State Medical
and Dental University and the Sechenov
Medical Academy in Moscow.
Domestic production of dental
equipment is insufficient for the
Russian market and very few new
products are produced domestically.
Local manufacturers such as Averon,
VladMiVa, Raduga Rossii, Geosoft,
Stomadent Omega, and Tselit produce a
wide range of dental equipment. Since
Russia’s domestic dental production
level meets only 20% of total demand,
imports play a significant role in the
market. The majority of dental
equipment is supplied from the United
States, Germany, France, Switzerland,
Japan, and other countries.
Many large U.S. and international
companies have offices in Russia,
including Densply, 3M, Nobel Biocare,
Mileston, Midmarek, 3i, Sirona, Kavo,
Colgate, Kodak-Eastman, PhilipsSonicare, Discuss Dental (now owned
by Philips), Oral B, and Wrigley Adeck.
There are about 500 distributors of
dental equipment in Russia. The major
distributors are located in Moscow and
work in other regions through smaller
local distributors or through regional
representatives. Import customs
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
77033
clearances are executed more easily in
larger cities like Moscow and St.
Petersburg. There are strict product
registration and certification procedures
necessary for the release of dental
equipment into the market. The
registration and certification process can
be complicated, time-consuming, and
expensive. It may require a regular
market presence by the manufacturer or
an authorized representative with
competent Russian language skills and
knowledge of the local market to be able
to complete the process.
Biotechnology
In the last several years, Russia has
been developing an innovative modern
economy by focusing on information
technologies and nanotechnologies. The
biotechnologies area has large potential
and is underdeveloped, but is evolving
because of the need to extend life
expectancies within the country.
LargeU.S. multinational companies like
Celgene, Amgen, and Genzyme are
established in the market and are
already working in the biotechnology
field. Despite the fact that major
companies from Europe and the U.S.
have already entered the market, there
is still room for small innovative
companies in the biotechnology area.
Good examples include two small U.S.
biotechnology companies, Bind and
Selecta, which have recently opened
offices in Russia to start research and
development, which is a priority of the
Russian government.
The Government Commission on High
Technologies and Innovations signed a
decision in April, 2011 to create a State
Coordination Program for the
Development of Biotechnology in the
Russian Federation through 2020. The
Ministry of Economic Development is
responsible for this State Coordination
Program, which focuses on several areas
including biopharmaceuticals and
biomedicine.
1. Biopharmaceuticals (essential
medicines, including biogenerics,
hormones, cytokines, therapeutic
monoclonal antibodies, peptides,
phytomedicines, new generation
vaccines, antibiotics and
bacteriophages)
2. Biomedicine (molecular
diagnostics, personalized medicine,
engineered cell and tissue for
therapeutic purposes, biocompatible
materials)
The Russian market for
biopharmaceuticals in 2010 was
estimated at $2.2 billion, of which $1.3
billion was dedicated to cytokines,
genetically engineered hormones
(including insulin), coagulants and
therapeutic enzymes, monoclonal
E:\FR\FM\31DEN1.SGM
31DEN1
77034
Federal Register / Vol. 77, No. 250 / Monday, December 31, 2012 / Notices
antibodies ($350 million), and vaccines
($350 million). For example, the sales of
antibodies and vaccines are expected to
rise to $480 million and $370 million
respectively by the year 2015.
The Russian biotechnology market is
focused on the development and
manufacturing of products for the
diagnosis and treatment of human
diseases and for the prevention of
harmful effects of the environment on
humans. The world market for
biotechnology (used for molecular
genetics diagnostic technologies) was
$13.5 billion in 2010, and is expected to
be $33.3 billion by 2015. The access to
credible data for the Russian market is
low because the segment has not been
fully developed, but it is expected to
mature in the near future.
Biotechnology is a large part of the
overall pharmaceutical sector.
According to industry experts, Russia is
currently one of the ten largest
pharmaceutical markets in the world. In
2011, the pharmaceutical market
volume amounted to $26 billion in end
user prices, which is 12% higher than
in 2010.
An important recent trend was the
planning and formation of
‘‘pharmaceutical clusters’’. This was
due in part to the completion of the
‘‘Strategy of Development of the
Pharmaceutical Industry- 2020’’,
developed by the Ministry of Industry
and Trade which outlines some
government priorities.
The Russian pharmaceutical market is
import driven with 76% of drugs taken
in Russia produced abroad. The only
domestic manufacturer in the top 20
leading players in the Russian
pharmaceutical market is
Pharmstandart.
Mission Goals
The goal of the Healthcare Trade
Mission to Russia is to promote the
export of U.S. goods and services by: (1)
Introducing U.S. companies to industry
representatives and potential clients and
partners; and (2) introducing U.S.
companies to industry experts to learn
about policy initiatives that will impact
the Russian healthcare industry in
general as well as the medical
equipment, dental equipment and
biotechnology sectors.
Mission Scenario
In Moscow, trade mission members
will participate in an Embassy briefing
from industry experts and take part in
one-on-one business appointments with
private-sector organizations. In addition,
they will enjoy a networking event with
industry leaders and potential partners.
In St. Petersburg, all of the delegates
will have customized one-on-one
business appointments and attend
another networking reception.
Matchmaking efforts will involve
partners such as the Association of
International Pharmaceutical
Manufacturers (AIPM), Innovative
Pharma, Association of International
Manufacturers of Medical Devices
(IMEDA), the American Chamber of
Commerce in Russia, and the Russian
Dental Association. U.S. participants
will be counseled before, during, and
after the mission by CS Russia staff
actively involved in the healthcare trade
mission.
PROPOSED TIME TABLE
Monday, June 3, Day 1 .............................
Tuesday, June 4, Day 2 ............................
Wednesday, June 5, Day 3 .......................
Thursday, June 6, Day 4 ...........................
Friday, June 7, Day 5 ................................
Moscow.
Briefing by the U.S. Embassy and industry experts.
Site Visits in afternoon.
Moscow.
One-on-one business appointments.
Networking reception.
Depart for St. Petersburg.
Travel day and free evening in St. Petersburg.
St. Petersburg.
One-on-one business appointments.
Networking reception.
St. Petersburg.
Additional meetings and follow-up appointments.
Departure for the United States (Friday evening or Saturday, June 8).
mstockstill on DSK4VPTVN1PROD with
Participation Requirements
All parties interested in participating
in the trade mission must be active in
the healthcare sector and complete and
submit an application package for
consideration by the Department of
Commerce. All applicants will be
evaluated on their ability to meet certain
conditions and best satisfy the selection
criteria as outlined below. A minimum
of 10 and maximum of 13 companies
will be selected to participate in the
mission from the applicant pool.
Applicants that are U.S. companies
already doing business in Russia as well
as those seeking to enter the Russian
market for the first time may apply.
Fees and Expenses
After a company has been selected to
participate in the mission, a payment to
VerDate Mar<15>2010
21:28 Dec 28, 2012
Jkt 229001
the Department of Commerce in the
form of a participation fee is required.
The participation fee will be $5950 for
large firms and $5350 for a small or
medium-sized enterprise (SME) trade
association, which will cover one
representative.* 1 The fee for an
additional representative (SME/trade
association or large company) is $750,
which will cover one representative.
The fee for an additional representative
(SME or large company) is $750.
1 An SME is defined as a firm with 500 or fewer
employees or that otherwise qualifies as a small
business under SBA regulations (see https://
www.sba.gov/services/contractingopportunities/
sizestandardstopics/). Parent companies,
affiliates, and subsidiaries will be considered when
determining business size. The dual pricing reflects
the Commercial Service’s user fee schedule that
became effective May 1, 2008 (see https://
www.export.gov/newsletter/march2008/
initiatives.html for additional information).
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
Expenses for travel, lodging, meals, and
incidentals will be the responsibility of
each mission participant. Delegation
members will be able to take advantage
of U.S. Embassy rates for hotel rooms
beginning Sunday, June 2 in Moscow
and through Saturday, June 8 in St.
Petersburg. Please note that the trade
mission begins in Moscow and ends in
St. Petersburg. Early arrival nights in
Moscow, return transportation to
Moscow from St. Petersburg, or the
extension of stay in St. Petersburg will
be the responsibility of the participants.
Conditions for Participation
An applicant must submit a
completed and signed mission
application and supplemental
application materials, including
adequate information on the company’s
products and/or services, primary
E:\FR\FM\31DEN1.SGM
31DEN1
Federal Register / Vol. 77, No. 250 / Monday, December 31, 2012 / Notices
market objectives, and goals for
participation. If the Department of
Commerce receives an incomplete
application, the Department may reject
the application, request additional
information, or take the lack of
information into account when
evaluating the applications.
Each applicant must also certify that
the products and services it seeks to
export through the mission are either
produced in the United States, or, if not,
marketed under the name of a U.S. firm
and have at least 51 percent U.S.
content of the value of the finished
product or service. In the case of a trade
association, the applicant must certify
that for each company to be represented
by the association, the products and/or
services the represented company seeks
to export are either produced in the
United States or, if not, marketed under
the name of a U.S. firm and have at least
fifty-one percent U.S. content.
mstockstill on DSK4VPTVN1PROD with
Criteria for Participation
Selection will be based on the
following criteria:
• Suitability of the company’s (or in
the case of a trade association, member
companies’) products or services to the
market.
• Applicant’s (or in the case of a trade
association, member companies’)
potential for business in Russia and in
the region, including likelihood of
exports resulting from the mission.
• Consistency of the applicant’s (or in
the case of a trade association, member
companies’) goals and objectives with
the stated scope of the mission.
Diversity of company size, sector or
subsector, and location may also be
considered during the review process.
Referrals from political organizations
and any documents containing
references to partisan political activities
(including political contributions) will
be removed from an applicant’s
submission and not considered during
the selection process.
Timeframe for Recruitment and
Applications
Mission recruitment will be
conducted in an open and public
manner, including publication in the
Federal Register, posting on the
Commerce Department trade mission
calendar (https://www.ita.doc.gov/
doctm/tmcal.html) and other Internet
web sites, press releases to general and
trade media, direct mail, notices by
industry trade associations and other
multiplier groups, and publicity at
industry meetings, symposia,
conferences, and trade shows. The U.S.
Department of Commerce will begin
reviewing applications and making
VerDate Mar<15>2010
21:28 Dec 28, 2012
Jkt 229001
selection decisions on a rolling basis
beginning on December 28, 2012 until
the maximum of 20 participants is
selected. Applications received after
March 15, 2013 will be considered only
if space and scheduling constraints
permit.
Contacts
Jessica Arnold, U.S. Commercial
Service, Washington, DC, Tel: (202)
482–2026, Jessica.Arnold@trade.gov.
Timothy Cannon, U.S. Commercial
Service, U.S. Embassy, Moscow, Tel:
+7 495 528 55 32,
Timothy.Cannon@trade.gov.
Yuliya Vinogradova, U.S. Commercial
Service, U.S. Embassy, Moscow, Tel:
+7 495 728 55 86,
Yuliya.Vinogradova@trade.gov.
77035
71778, first column, correct the subject
heading of the notice to read: U.S.
Infrastructure Trade Mission to
Colombia and Panama; Bogota,
Columbia and Panama City, Panama,
May 13–16, 2013.
Dated: December 13, 2012
Elnora Moye,
Trade Program Assistant.
[FR Doc. 2012–31426 Filed 12–28–12; 8:45 am]
BILLING CODE 3510–FP–P
DEPARTMENT OF COMMERCE
National Institute of Standards and
Technology
Elnora Moye,
Trade Program Assistant.
Proposed Information Collection;
Comment Request; Malcolm Baldrige
National Quality Award and Examiner
Applications
[FR Doc. 2012–31425 Filed 12–28–12; 8:45 am]
AGENCY:
BILLING CODE 3510–FP–P
National Institute of Standards
and Technology (NIST), Commerce.
ACTION: Notice.
DEPARTMENT OF COMMERCE
SUMMARY:
International Trade Administration
U.S. Infrastructure Trade Mission to
Colombia and Panama; Bogota,
Columbia and Panama City, Panama,
May 13–16, 2012; Correction
International Trade
Administration, Department of
Commerce.
ACTION: Notice; Correction.
AGENCY:
The United States Department
of Commerce, International Trade
Administration, U.S. and Foreign
Commercial Service published a
document in the Federal Register of
December 4, 2012 regarding the U.S.
Infrastructure Trade Mission to
Colombia and Panama May 13–16,
2013. The subject heading of the
document incorrectly indicated the year
2012 instead of 2013. All other
information in the December 4, 2012
Notice, including the February 15, 2013
application deadline, is correct.
FOR FURTHER INFORMATION CONTACT:
Arica N Young, Commercial Service
Trade Missions Program, Tel: 202–482–
6219, Fax: 202–482–9000, Email:
arica.young@trade.gov; or Carlos
Suarez, U.S. Commercial Service
Colombia, Tel: 57–1–2752519, Email:
carlos.suarez@trade.gov; or Enrique
Tellez, U.S. Commercial Service
Panama, Tel: 507–317–5080, Email:
enrique.tellez@trade.gov.
SUMMARY:
Correction
In the Federal Register of December 4,
2012, in FR Doc. 2012–29306 on page
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
The Department of
Commerce, as part of its continuing
effort to reduce paperwork and
respondent burden, invites the general
public and other Federal agencies to
take this opportunity to comment on
proposed and/or continuing information
collections, as required by the
Paperwork Reduction Act of 1995.
DATES: Written comments must be
submitted on or before March 1, 2013.
ADDRESSES: Direct all written comments
to Jennifer Jessup, Departmental
Paperwork Clearance Officer,
Department of Commerce, Room 6616,
14th and Constitution Avenue NW.,
Washington, DC 20230 (or via the
Internet at jjessup@doc.gov).
FOR FURTHER INFORMATION CONTACT:
Requests for additional information or
copies of the information collection
instrument and instructions should be
directed to Dawn Bailey, Baldrige
Performance Excellence Program, 100
Bureau Drive, Stop 1020, National
Institute of Standards and Technology,
Gaithersburg, Maryland 20899–1020;
telephone (301) 975–3074, fax (301)
948–3716, email dawn.bailey@nist.gov.
SUPPLEMENTARY INFORMATION:
I. Abstract
The Department of Commerce is
responsible for the Baldrige
Performance Excellence Program (BPEP)
and the Malcolm Baldrige National
Quality (BNQP) Award. Directly
associated with this Award is the Board
of Examiners, an integral volunteer
workforce for BPEP (managed by NIST).
An applicant for the MBNQA is
E:\FR\FM\31DEN1.SGM
31DEN1
Agencies
[Federal Register Volume 77, Number 250 (Monday, December 31, 2012)]
[Notices]
[Pages 77032-77035]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-31425]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
International Trade Administration
Healthcare Trade Mission to Russia, June 3-7, 2013
AGENCY: International Trade Administration, Department of Commerce.
ACTION: Notice.
-----------------------------------------------------------------------
Mission Description
The U.S. Department of Commerce, International Trade
Administration, U.S. and Foreign Commercial Service (CS), is organizing
a Healthcare Trade Mission to Moscow and St. Petersburg, Russia from
June 3-7, 2013 which will be led by a senior Commerce official.
Russia, with 140 million consumers and rapidly growing demand for
healthcare products and services, presents lucrative opportunities for
U.S. companies. Equipment, technologies, and investments are needed in
the healthcare sector, specifically in the medical equipment, dental
equipment and biotechnology sub-sectors. This healthcare mission will
directly contribute to the National Export Initiative (NEI) by
assisting U.S. businesses in entering the Russian healthcare market and
increasing U.S. exports. It will also be a deliverable for the U.S.-
Russia Bilateral Presidential Commission Business Development and
Economic Relations Working Group.
The mission will help participants gain market insights, make
industry contacts, solidify business strategies, and advance specific
projects with the goal of increasing U.S. exports to Russia. The
mission will include one-on-one business appointments with pre-screened
potential partners, market briefings, and networking events. Joining
this official U.S. delegation will provide participating companies an
opportunity to assess the Russian healthcare market.
Commercial Setting
Russia is one of the world's fastest growing economies and its
healthcare system is evolving rapidly with a promising outlook for U.S.
healthcare exports, particularly in the medical equipment, dental
equipment and biotechnology subsectors. Russia's National Health
Project aims at improving access and funding for healthcare and
improving Russia's healthcare sector, and has created opportunities for
increased U.S. exports in the healthcare sector.
Approximately 20% of overall health care spending is covered out-
of- pocket by patients. Voluntary healthcare insurance programs
currently account for approximately one-third of total private
healthcare expenditures. According to future reform plans, mandatory
insurance funds will serve as the main source of healthcare funding and
will provide transparency and monetary control within the system.
The National Health Project was signed by President Putin in 2005
and was designed to significantly improve Russian healthcare. From
2011-2013, $15.4 billion was allocated from both the federal budget and
the Mandatory Healthcare Insurance Fund [to the National Health
Project?]. The Program of Modernization in Healthcare 2011-2012, aimed
at renovating and upgrading healthcare facilities, was financed at $11
billion. The significant funding reflects the current need for new
modern technologies for diagnostics and treatment. Russian patients are
becoming more aware of modern medical technologies around the world and
expect the same types of treatment in Russia.
In addition to these programs that are currently being implemented,
the Ministry of Health has recently developed a draft government
program called ``Development of Healthcare in the Russian Federation.''
This document is currently under review for approval. It contains the
principles of preventive
[[Page 77033]]
medicine, quality of provided healthcare services, education of medical
personnel, and overall changes in the healthcare infrastructure.
The Ministry of Industry and Trade is also currently developing a
strategy for the development of the medical industry through 2020. With
continued growth in this sector, World Trade Organization (WTO)
accession, and government plans to modernize and invest in Russian
healthcare through 2020, American companies should be poised to make
significant contributions to the Russian healthcare market.
Medical Equipment
The medical equipment sector is one of the fastest-growing sectors
of the economy. There is a relatively stable macroeconomic situation in
Russia with much unsatisfied deferred demand for medical equipment
across the country. In addition, the Russian government is focused on
this sector and has increased government financing for the purchase of
medical equipment. For example, the Program of High-Tech Medical
Assistance 2011-2013 was financed at $4 billion.
In 2011, the market for medical equipment was estimated at $4.9
billion. During the next nine years, experts expect yearly market
growth to be 13.5%. The most promising market segments include
diagnostics and visualization, cardiovascular, ophthalmology,
orthopedics, laboratory diagnostics and urology equipment and
technology. For example, the average annual increase from 2006-2011 in
market share for diagnostics and visualization equipment was 18% and in
medical IT 10%.
Since commercialization of medical equipment manufactured in Russia
remains low, the market for medical equipment is heavily dependent on
imports. The average annual increase in the import market for medical
equipment from 2006 to 2011 was approximately 23%. Medical equipment
imports in 2006 were $14.2 billion, with steady growth to $41 billion
in 2011.
Membership in the WTO will also benefit foreign exports to Russia.
After full implementation of the WTO accession and Permanent Normal
Trade Relations, tariffs for medical equipment are estimated to range
from 0% to 7%. Currently, tariffs range as high as 15% to 20%.
Dental Equipment
The Russian dental market is also a sector that is expanding and
showing good growth potential. In 2011, total world imports into Russia
for dental equipment were approximately $500 million, reflecting the
need for dental equipment for use in the large market for dental
services in Russia, which was approximately $6 billion in 2011.
The number of clinics, practicing dentists, technicians and patient
visits are all on the rise. There are over 9,500 dental units operating
in Moscow, with 3,000 state clinics and over 6,500 private clinics.
There are 670 municipal dental clinics and 2900 dental departments
within those clinics. The highest level of dental industry
privatization is in the Moscow region.
The number of practicing dentists in Russia is 68,000, of which
35,000 are members of the Russian Dental Association. The number of
patient visits is approximately 150 million a year. However, the ratio
of dentists to patients in Russia is still only 45/100,000 people,
which is below levels in the United States and most European countries.
In the United States, the ratio of patients to dentists is 60/100,000.
The dental market is one of the most organized markets in Russia.
The largest associations are the Russian Dental Association, which has
69 regional divisions and the Dental Industry (DI ROSI) which has 45
member companies. These associations play an important role in the
introduction of new technologies and practices, actively participate in
trade events, and regularly publish in professional journals. As a
result, they have a large impact on the industry. The two major dental
universities are Moscow State Medical and Dental University and the
Sechenov Medical Academy in Moscow.
Domestic production of dental equipment is insufficient for the
Russian market and very few new products are produced domestically.
Local manufacturers such as Averon, VladMiVa, Raduga Rossii, Geosoft,
Stomadent Omega, and Tselit produce a wide range of dental equipment.
Since Russia's domestic dental production level meets only 20% of total
demand, imports play a significant role in the market. The majority of
dental equipment is supplied from the United States, Germany, France,
Switzerland, Japan, and other countries.
Many large U.S. and international companies have offices in Russia,
including Densply, 3M, Nobel Biocare, Mileston, Midmarek, 3i, Sirona,
Kavo, Colgate, Kodak-Eastman, Philips-Sonicare, Discuss Dental (now
owned by Philips), Oral B, and Wrigley Adeck.
There are about 500 distributors of dental equipment in Russia. The
major distributors are located in Moscow and work in other regions
through smaller local distributors or through regional representatives.
Import customs clearances are executed more easily in larger cities
like Moscow and St. Petersburg. There are strict product registration
and certification procedures necessary for the release of dental
equipment into the market. The registration and certification process
can be complicated, time-consuming, and expensive. It may require a
regular market presence by the manufacturer or an authorized
representative with competent Russian language skills and knowledge of
the local market to be able to complete the process.
Biotechnology
In the last several years, Russia has been developing an innovative
modern economy by focusing on information technologies and
nanotechnologies. The biotechnologies area has large potential and is
underdeveloped, but is evolving because of the need to extend life
expectancies within the country. LargeU.S. multinational companies like
Celgene, Amgen, and Genzyme are established in the market and are
already working in the biotechnology field. Despite the fact that major
companies from Europe and the U.S. have already entered the market,
there is still room for small innovative companies in the biotechnology
area. Good examples include two small U.S. biotechnology companies,
Bind and Selecta, which have recently opened offices in Russia to start
research and development, which is a priority of the Russian
government.
The Government Commission on High Technologies and Innovations
signed a decision in April, 2011 to create a State Coordination Program
for the Development of Biotechnology in the Russian Federation through
2020. The Ministry of Economic Development is responsible for this
State Coordination Program, which focuses on several areas including
biopharmaceuticals and biomedicine.
1. Biopharmaceuticals (essential medicines, including biogenerics,
hormones, cytokines, therapeutic monoclonal antibodies, peptides,
phytomedicines, new generation vaccines, antibiotics and
bacteriophages)
2. Biomedicine (molecular diagnostics, personalized medicine,
engineered cell and tissue for therapeutic purposes, biocompatible
materials)
The Russian market for biopharmaceuticals in 2010 was estimated at
$2.2 billion, of which $1.3 billion was dedicated to cytokines,
genetically engineered hormones (including insulin), coagulants and
therapeutic enzymes, monoclonal
[[Page 77034]]
antibodies ($350 million), and vaccines ($350 million). For example,
the sales of antibodies and vaccines are expected to rise to $480
million and $370 million respectively by the year 2015.
The Russian biotechnology market is focused on the development and
manufacturing of products for the diagnosis and treatment of human
diseases and for the prevention of harmful effects of the environment
on humans. The world market for biotechnology (used for molecular
genetics diagnostic technologies) was $13.5 billion in 2010, and is
expected to be $33.3 billion by 2015. The access to credible data for
the Russian market is low because the segment has not been fully
developed, but it is expected to mature in the near future.
Biotechnology is a large part of the overall pharmaceutical sector.
According to industry experts, Russia is currently one of the ten
largest pharmaceutical markets in the world. In 2011, the
pharmaceutical market volume amounted to $26 billion in end user
prices, which is 12% higher than in 2010.
An important recent trend was the planning and formation of
``pharmaceutical clusters''. This was due in part to the completion of
the ``Strategy of Development of the Pharmaceutical Industry- 2020'',
developed by the Ministry of Industry and Trade which outlines some
government priorities.
The Russian pharmaceutical market is import driven with 76% of
drugs taken in Russia produced abroad. The only domestic manufacturer
in the top 20 leading players in the Russian pharmaceutical market is
Pharmstandart.
Mission Goals
The goal of the Healthcare Trade Mission to Russia is to promote
the export of U.S. goods and services by: (1) Introducing U.S.
companies to industry representatives and potential clients and
partners; and (2) introducing U.S. companies to industry experts to
learn about policy initiatives that will impact the Russian healthcare
industry in general as well as the medical equipment, dental equipment
and biotechnology sectors.
Mission Scenario
In Moscow, trade mission members will participate in an Embassy
briefing from industry experts and take part in one-on-one business
appointments with private-sector organizations. In addition, they will
enjoy a networking event with industry leaders and potential partners.
In St. Petersburg, all of the delegates will have customized one-on-one
business appointments and attend another networking reception.
Matchmaking efforts will involve partners such as the Association
of International Pharmaceutical Manufacturers (AIPM), Innovative
Pharma, Association of International Manufacturers of Medical Devices
(IMEDA), the American Chamber of Commerce in Russia, and the Russian
Dental Association. U.S. participants will be counseled before, during,
and after the mission by CS Russia staff actively involved in the
healthcare trade mission.
Proposed Time Table
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
Monday, June 3, Day 1............................................ Moscow.
Briefing by the U.S. Embassy and industry
experts.
Site Visits in afternoon.
Tuesday, June 4, Day 2........................................... Moscow.
One-on-one business appointments.
Networking reception.
Wednesday, June 5, Day 3......................................... Depart for St. Petersburg.
Travel day and free evening in St.
Petersburg.
Thursday, June 6, Day 4.......................................... St. Petersburg.
One-on-one business appointments.
Networking reception.
Friday, June 7, Day 5............................................ St. Petersburg.
Additional meetings and follow-up
appointments.
Departure for the United States (Friday
evening or Saturday, June 8).
----------------------------------------------------------------------------------------------------------------
Participation Requirements
All parties interested in participating in the trade mission must
be active in the healthcare sector and complete and submit an
application package for consideration by the Department of Commerce.
All applicants will be evaluated on their ability to meet certain
conditions and best satisfy the selection criteria as outlined below. A
minimum of 10 and maximum of 13 companies will be selected to
participate in the mission from the applicant pool. Applicants that are
U.S. companies already doing business in Russia as well as those
seeking to enter the Russian market for the first time may apply.
Fees and Expenses
After a company has been selected to participate in the mission, a
payment to the Department of Commerce in the form of a participation
fee is required. The participation fee will be $5950 for large firms
and $5350 for a small or medium-sized enterprise (SME) trade
association, which will cover one representative.* \1\ The fee for an
additional representative (SME/trade association or large company) is
$750, which will cover one representative. The fee for an additional
representative (SME or large company) is $750. Expenses for travel,
lodging, meals, and incidentals will be the responsibility of each
mission participant. Delegation members will be able to take advantage
of U.S. Embassy rates for hotel rooms beginning Sunday, June 2 in
Moscow and through Saturday, June 8 in St. Petersburg. Please note that
the trade mission begins in Moscow and ends in St. Petersburg. Early
arrival nights in Moscow, return transportation to Moscow from St.
Petersburg, or the extension of stay in St. Petersburg will be the
responsibility of the participants.
---------------------------------------------------------------------------
\1\ An SME is defined as a firm with 500 or fewer employees or
that otherwise qualifies as a small business under SBA regulations
(see https://www.sba.gov/services/contractingopportunities/sizestandardstopics/). Parent companies, affiliates, and
subsidiaries will be considered when determining business size. The
dual pricing reflects the Commercial Service's user fee schedule
that became effective May 1, 2008 (see https://www.export.gov/newsletter/march2008/initiatives.html for additional information).
---------------------------------------------------------------------------
Conditions for Participation
An applicant must submit a completed and signed mission application
and supplemental application materials, including adequate information
on the company's products and/or services, primary
[[Page 77035]]
market objectives, and goals for participation. If the Department of
Commerce receives an incomplete application, the Department may reject
the application, request additional information, or take the lack of
information into account when evaluating the applications.
Each applicant must also certify that the products and services it
seeks to export through the mission are either produced in the United
States, or, if not, marketed under the name of a U.S. firm and have at
least 51 percent U.S. content of the value of the finished product or
service. In the case of a trade association, the applicant must certify
that for each company to be represented by the association, the
products and/or services the represented company seeks to export are
either produced in the United States or, if not, marketed under the
name of a U.S. firm and have at least fifty-one percent U.S. content.
Criteria for Participation
Selection will be based on the following criteria:
Suitability of the company's (or in the case of a trade
association, member companies') products or services to the market.
Applicant's (or in the case of a trade association, member
companies') potential for business in Russia and in the region,
including likelihood of exports resulting from the mission.
Consistency of the applicant's (or in the case of a trade
association, member companies') goals and objectives with the stated
scope of the mission.
Diversity of company size, sector or subsector, and location may
also be considered during the review process.
Referrals from political organizations and any documents containing
references to partisan political activities (including political
contributions) will be removed from an applicant's submission and not
considered during the selection process.
Timeframe for Recruitment and Applications
Mission recruitment will be conducted in an open and public manner,
including publication in the Federal Register, posting on the Commerce
Department trade mission calendar (https://www.ita.doc.gov/doctm/tmcal.html) and other Internet web sites, press releases to general and
trade media, direct mail, notices by industry trade associations and
other multiplier groups, and publicity at industry meetings, symposia,
conferences, and trade shows. The U.S. Department of Commerce will
begin reviewing applications and making selection decisions on a
rolling basis beginning on December 28, 2012 until the maximum of 20
participants is selected. Applications received after March 15, 2013
will be considered only if space and scheduling constraints permit.
Contacts
Jessica Arnold, U.S. Commercial Service, Washington, DC, Tel: (202)
482-2026, Jessica.Arnold@trade.gov.
Timothy Cannon, U.S. Commercial Service, U.S. Embassy, Moscow, Tel: +7
495 528 55 32, Timothy.Cannon@trade.gov.
Yuliya Vinogradova, U.S. Commercial Service, U.S. Embassy, Moscow, Tel:
+7 495 728 55 86, Yuliya.Vinogradova@trade.gov.
Elnora Moye,
Trade Program Assistant.
[FR Doc. 2012-31425 Filed 12-28-12; 8:45 am]
BILLING CODE 3510-FP-P